Home-Based Respiratory Muscle Strength Training Program for Individuals With Post-COVID-19 Persistent Dyspnea

Sponsor
University of South Florida (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06091280
Collaborator
(none)
20
1
1
15
1.3

Study Details

Study Description

Brief Summary

To evaluate the extent to which a 12-week respiratory rehabilitation program consisting of inspiratory and expiratory breathing exercises compared to expiratory breathing exercises alone will help to improve shortness of breath, respiratory symptoms, breathing function, distance walked, and quality of life in those who are experiencing persistent shortness of breath after having had COVID-19. Measurements will take place at the beginning, 6 weeks, and at 12 weeks in the study.

Condition or Disease Intervention/Treatment Phase
  • Device: Respiratory Muscle Strength Trainers
N/A

Detailed Description

To evaluate the extent to which a 12-week respiratory rehabilitation program consisting of inspiratory and expiratory muscle strength training exercises as compared to a prior study of expiratory muscle strength training alone is effective in improving dyspnea, respiratory symptoms, quantitative measures of pulmonary function, physical performance, and quality of life in individuals reporting persistent dyspnea post-COVID-19 at baseline, six and twelve weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single-group, longitudinal, intervention studySingle-group, longitudinal, intervention study
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Home-Based Respiratory Muscle Strength Training Program for Individuals With Post-COVID-19 Persistent Dyspnea
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Respiratory Muscle Strength Training

Pursed Lip Breathing: Participants will perform two sets of 10 repetitions twice per day. Inspiratory Muscle Strength Training (IMST): The participant will use an IMST trainer provided by the study (Threshold Inspiratory Muscle Strength Trainer). This exercise is repeated for a 3-minute duration, followed by a rest period of 2 minutes. This cycle is repeated for 6 cycles over a 30-minute timespan. This exercise will be performed 3 times/week on alternating days. Expiratory Muscle Strength Training (EMST): The participant will use an EMST trainer (EMST 150) provided by the study. This exercise is repeated for a 3-minute duration, followed by a rest period of 2 minutes. The cycle is repeated for 6 cycles over a 30-minute timespan. This exercise will be performed 3 x/week on opposite days of the inspiratory muscle strength training.

Device: Respiratory Muscle Strength Trainers
Devices provided to each participant. Resistance loading set at less than 50% of the peak inspiratory and peak expiratory flow rate.
Other Names:
  • Threshold Inspiratory Muscle Strength Trainer
  • Expiratory Muscle Strength Trainer (EMST 150)
  • Outcome Measures

    Primary Outcome Measures

    1. Modified Medical Research Council Scale [Baseline, 6-weeks, and 12-week measurements]

      Scale of 0-4 with 4 being the most severe dyspnea.

    2. COPD Assessment Test [Baseline, 6-weeks, and 12-week measurements.]

      8-item questionnaire with a semantic, 6-point differential scale for each item. Scores range from 0-40 with higher scores indicating more severe respiratory symptoms.

    3. Forced Expiratory Volume over 1 second (FEV1) [Baseline, 6-weeks, and 12-week measurements]

      Using the Microlife Digital Peak Flow and FEV1 Meter (Clearwater, FL).

    4. Peak Inspiratory Flow [Baseline, 6-weeks, and 12-week measurements.]

      Using the In-Check Peak Inspiratory Flow meter (Granbury, TX).

    5. Thoracic Expansion Measures [Baseline, 6-weeks, and 12-week measurements]

      Gulick tape measure positioned around the participant's chest at the 4th intercostal space. Participant breathes in and out as far as possible and the difference between the 2 values equals thoracic expansion.

    6. Physical Capacity [Baseline, 6-weeks, and 12-week measurements.]

      6 Minute Walk Test following the American Thoracic Society Procedure: 50-meter distance is marked. Participant walks as quickly as possible for 6 minutes. Results recorded in meters. Vital signs and oxygen saturation monitored and recorded.

    7. EuroQoL-5 Dimension-5 Level [Baseline, 6-weeks, and 12-week measurements.]

      EuroQoL-5 Dimension-5 Level to evaluate 5 dimensions of quality of life including mobility, self-care, usual activities, discomfort and pain, anxiety, and depression. Each is scored using a 5-point semantic scale.

    Secondary Outcome Measures

    1. Feasibility and Acceptability of the Intervention [12-weeks.]

      Recruitment and retention rates. 5-item questionnaire asking participants about the exercise protocol.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Self-reported history of a positive COVID-19 diagnosis in the past.

    • Able to walk independently

    • Cognitively intact

    • English-speaking

    • Dyspnea at rest or with activity rated at 3 or greater on the Dyspnea on Exertion scale.

    • May use oxygen.

    • May be taking medications.

    Exclusion Criteria:
    • Individuals who are wheelchair bound or who cannot walk independently.

    • Individuals hospitalized for COVID-19 who self-report that they received mechanical ventilation during hospitalization.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of South Florida Tampa Florida United States 33620

    Sponsors and Collaborators

    • University of South Florida

    Investigators

    • Principal Investigator: Constance Visovsky, PhD, University of South Florida

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of South Florida
    ClinicalTrials.gov Identifier:
    NCT06091280
    Other Study ID Numbers:
    • 006272
    First Posted:
    Oct 19, 2023
    Last Update Posted:
    Oct 19, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by University of South Florida
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 19, 2023